Guardant Health Inc

Guardant Health insider buys 264 shares amid new ctDNA breakthroughs & analyst upgrades; investors see future upside despite recent price dips.

Guardant Health insider buying shows cautious optimism amid volatile markets. Explore how executives’ small purchases signal confidence in tech‑driven diagnostics, reimbursement shifts, and future growth potential.